CAPR vs TLRY · $1.62B cap vs rev $915.5M
Capricor Therapeutics Inc (CAPR) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Capricor Therapeutics Inc (CAPR) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported CAPR revenue for 2025-12-31 was $0. Net income was -$105.0M. CAPR currently screens at market cap $1.62B.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
CAPR currently screens at market cap $1.62B. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the CAPR and TLRY stock pages for the full models.
Not investment advice.